| Arlington Family Chiropractic Pllc | |
|
20218 77th Ave Ne, Suite A, Arlington, WA 98223-4602 | |
| (360) 435-3900 | |
| (360) 435-1105 |
| Full Name | Arlington Family Chiropractic Pllc |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 20218 77th Ave Ne, Arlington, Washington |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205059474 | NPI | - | NPPES |
| 0194568 | Other | WA | LABOR AND INDUSTRIES |
| 130156 | Other | WA | LABORN AND INDUSTRIES |
| 2542GA | Other | WA | BLUE SHIELD |
| 0151161 | Other | WA | LABOR AND INDUSTRIES |
| 210186 | Other | WA | LABOR AND INDUSTRIES |
| 218748 | Other | WA | LABOR AND INDUSTRIES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | CH00003609 (Washington) | Primary |
| Provider Name | Brice P Kovarik |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1538208855 PECOS PAC ID: 3971594268 Enrollment ID: I20040524001401 |
News Archive
Myriad Genetics announced today that it is rapidly nearing completion of the preclinical data package on MPC-0920, its antithrombin drug candidate, for submission to the FDA prior to beginning human clinical trials.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
A special feature in this week's issue of the journal Science highlights protein array technology, touching on research conducted by Joshua LaBaer, director of the Biodesign Institute's Virginia G. Piper Center for Personalized Diagnostics.
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since 2015 also for the treatment of adults with Waldenström macroglobulinaemia. Regarding the treatment of patients with CLL or MCL, the Federal Joint Committee (G-BA) already conducted a benefit assessment and made a decision in 2015.
New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery.
› Verified 8 days ago
| Provider Name | Shawn L Gay |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1578591566 PECOS PAC ID: 2668435934 Enrollment ID: I20041109000175 |
News Archive
Myriad Genetics announced today that it is rapidly nearing completion of the preclinical data package on MPC-0920, its antithrombin drug candidate, for submission to the FDA prior to beginning human clinical trials.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
A special feature in this week's issue of the journal Science highlights protein array technology, touching on research conducted by Joshua LaBaer, director of the Biodesign Institute's Virginia G. Piper Center for Personalized Diagnostics.
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since 2015 also for the treatment of adults with Waldenström macroglobulinaemia. Regarding the treatment of patients with CLL or MCL, the Federal Joint Committee (G-BA) already conducted a benefit assessment and made a decision in 2015.
New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Arlington Family Chiropractic Pllc 20218 77th Ave Ne, Suite A, Arlington, WA 98223-4602 Ph: (360) 435-3900 | Arlington Family Chiropractic Pllc 20218 77th Ave Ne, Suite A, Arlington, WA 98223-4602 Ph: (360) 435-3900 |
News Archive
Myriad Genetics announced today that it is rapidly nearing completion of the preclinical data package on MPC-0920, its antithrombin drug candidate, for submission to the FDA prior to beginning human clinical trials.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
A special feature in this week's issue of the journal Science highlights protein array technology, touching on research conducted by Joshua LaBaer, director of the Biodesign Institute's Virginia G. Piper Center for Personalized Diagnostics.
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since 2015 also for the treatment of adults with Waldenström macroglobulinaemia. Regarding the treatment of patients with CLL or MCL, the Federal Joint Committee (G-BA) already conducted a benefit assessment and made a decision in 2015.
New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery.
› Verified 8 days ago
Welly Chiropractic Ps Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 17432 Smokey Point Blvd Ste 105, Arlington, WA 98223 Phone: 360-653-2222 Fax: 360-653-5730 | |
Dr. Michael Thomas Breneman, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 18619 Heron Ct, 18619 Heron Ct, Arlington, WA 98223 Phone: 360-913-3116 | |
Active Balance Chiropractic Chiropractor Medicare: Medicare Enrolled Practice Location: 17432 Smokey Point Blvd Ste 105, Arlington, WA 98223 Phone: 360-653-2222 | |
Ronning Chiropractic Pllc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 3116a 188th St Ne, Arlington, WA 98223 Phone: 360-653-8307 | |
Dr. Scott William Peseau, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 215 E 3rd St, Arlington, WA 98223 Phone: 360-474-9900 Fax: 360-474-8064 | |
Lonald A Welly, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 17432 Smokey Pt Blvd, Ste 105, Arlington, WA 98223 Phone: 360-653-2222 | |
Levi Cadman, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 20218 77th Ave Ne Ste A, Arlington, WA 98223 Phone: 360-435-3900 |